Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Krishna Padmanabhan

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Biometrical Journal. Biometrische Zeitschrift|October 5, 2010
Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpointS Krishna Padmanabhan, Vladimir Dragalin
Journal of Biopharmaceutical Statistics|November 21, 2007
Adaptive designs for dose-finding studies based on sigmoid Emax modelVladimir Dragalin, Francis Hsuan, S Krishna Padmanabhan
Journal of Biopharmaceutical Statistics|January 19, 2012
A bayesian dose-finding design adapting to efficacy and tolerability responseS Krishna Padmanabhan, Scott Berry, Vladimir Dragalin, et al.
International Clinical Psychopharmacology|June 4, 2005
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placeboCharles Shelton, Richard Entsuah, S Krishna Padmanabhan, et al.
The Primary Care Companion for CNS Disorders|October 7, 2011
A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorderKaren A Tourian, Bruno Pitrosky, S Krishna Padmanabhan, et al.
CNS Spectrums|January 27, 2009
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorderAlan D Feiger, Karen A Tourian, Gregory R Rosas, et al.
Clinical Therapeutics|August 25, 2009
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studiesKaren A Tourian, S Krishna Padmanabhan, James Groark, et al.
Innovations in Clinical Neuroscience|August 24, 2011
How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case StudyJoan Shen, Sheldon Preskorn, Vladimir Dragalin, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Biometrical Journal. Biometrische Zeitschrift|October 5, 2010
Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpointS Krishna Padmanabhan, Vladimir Dragalin
Journal of Biopharmaceutical Statistics|November 21, 2007
Adaptive designs for dose-finding studies based on sigmoid Emax modelVladimir Dragalin, Francis Hsuan, S Krishna Padmanabhan
Journal of Biopharmaceutical Statistics|January 19, 2012
A bayesian dose-finding design adapting to efficacy and tolerability responseS Krishna Padmanabhan, Scott Berry, Vladimir Dragalin, et al.
International Clinical Psychopharmacology|June 4, 2005
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placeboCharles Shelton, Richard Entsuah, S Krishna Padmanabhan, et al.
The Primary Care Companion for CNS Disorders|October 7, 2011
A 10-month, open-label evaluation of desvenlafaxine in outpatients with major depressive disorderKaren A Tourian, Bruno Pitrosky, S Krishna Padmanabhan, et al.
CNS Spectrums|January 27, 2009
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorderAlan D Feiger, Karen A Tourian, Gregory R Rosas, et al.
Clinical Therapeutics|August 25, 2009
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studiesKaren A Tourian, S Krishna Padmanabhan, James Groark, et al.
Innovations in Clinical Neuroscience|August 24, 2011
How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case StudyJoan Shen, Sheldon Preskorn, Vladimir Dragalin, et al.
Pageof 1